搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Complement C1q tumor necrosis factor-related protein 9A(C1QTNF9) ELISA kit

Human Complement C1q tumor necrosis factor-related protein 9A(C1QTNF9) ELISA kit

  • 中文名稱：
    人補(bǔ)體C1q腫瘤壞死因子相關(guān)蛋白9A(C1QTNF9)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL003654HU
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人補(bǔ)體C1q腫瘤壞死因子相關(guān)蛋白9A(C1QTNF9)酶聯(lián)免疫試劑盒（CSB-EL003654HU）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿、組織勻漿樣本中的C1QTNF9含量。試劑盒檢測(cè)范圍為0.312 ng/mL-20 ng/mL，產(chǎn)品適用于基礎(chǔ)研究領(lǐng)域，例如探究代謝性疾病動(dòng)物模型的蛋白表達(dá)變化、評(píng)估炎癥相關(guān)信號(hào)通路調(diào)控機(jī)制，或用于體外培養(yǎng)細(xì)胞中C1QTNF9分泌水平的動(dòng)態(tài)監(jiān)測(cè)，為疾病機(jī)制研究與藥物開(kāi)發(fā)提供可靠工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書。
  • 別名：
    C1QTNF9 ELISA kit; C1QTNF9A ELISA kit; UNQ6503/PRO21380Complement C1q and tumor necrosis factor-related protein 9A ELISA kit; Complement C1q and tumor necrosis factor-related protein 9 ELISA kit
  • 縮寫：
    C1QTNF9
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測(cè)范圍：
    0.312 ng/mL-20 ng/mL
  • 靈敏度：
    0.078 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Others
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human C1QTNF9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    SampleSerum(n=4)
    1:1Average %97
    Range %91-101
    1:2Average %101
    Range %95-104
    1:4Average %92
    Range %85-95
    1:8Average %100
    Range %94-103
  • 回收率：
    The recovery of human C1QTNF9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9185-96
    EDTA plasma (n=4)9082-94
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/mlOD1OD2AverageCorrected
    202.840 2.799 2.820 2.711
    102.104 1.997 2.051 1.942
    51.171 1.151 1.161 1.052
    2.50.532 0.523 0.528 0.419
    1.250.349 0.358 0.354 0.245
    0.6250.233 0.242 0.238 0.129
    0.3120.161 0.157 0.159 0.050
    00.111 0.107 0.109
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Probable adipokine. Activates AMPK, AKT, and p44/42 MAPK signaling pathways.
  • 基因功能參考文獻(xiàn)：
    1. suggesting the protective potentials of C1q tumour necrosis factor-related protein 9 in the progression of peripheral arterial disease in human type 2 diabetes mellitus PMID: 29543038
    2. Authors demonstrate that CTRP9 regulates growth, differentiation, and apoptosis of HaCaT human keratinocytes. We found that CTRP9 augmented expression of transforming growth factor beta 1 (TGFbeta1) by transcription factor activator protein 1 (AP-1) binding activity and phosphorylation of p38 in a dose-dependent manner. PMID: 29145717
    3. CTRP9 inhibits the cholesterol-induced Vascular smooth muscle cell phenotype switch and cell dysfunction by activating PRKAA1. PMID: 28524645
    4. results revealed increased circulating levels of CTRP9 in T2DM and CAD individuals which suggests a compensatory response to insulin resistance, inflammatory milieu and endothelial dysfunction; however, more studies are needed to confirm this PMID: 29381773
    5. CTRP9 levels are elevated in obesity and significantly decrease following weight loss surgery. PMID: 26982010
    6. Plasma CTRP9 levels are associated with atherosclerosis in diabetic patients without CKD, independently of obesity, adiponectin, and traditional cardiovascular risk factors PMID: 28070523
    7. The up-regulation of CTRP9 during hypertrophic heart disease facilitates maladaptive cardiac remodeling and left ventricular dysfunction. PMID: 27821723
    8. Results demonstrate that CTRP9 alleviates hepatic steatosis through relief of endoplasmic reticulum stress via the AMPK-mediated induction of autophagy. PMID: 26419929
    9. Study demonstrates that CTRP9 attenuates cytokine-induced vascular inflammation in endothelial cells mediated by AMPK activation. PMID: 26523509
    10. Circulating and coronary CTRP9 plays an important role in the inflammation and coronary atherosclerosis of CAD patients. Serum CTRP9 is an independent protective factor of CAD PMID: 26457306
    11. Serum CTRP9 concentration was significantly and positively associated with arterial stiffness in patients with type 2 diabetes PMID: 25105737
    12. Serum CTRP9 concentrations were positively associated with favorable glucose or metabolic phenotypes and absence of metabolic syndrome, independent of serum total adiponectin concentrations. PMID: 24357853

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 組織特異性：
    Expressed predominantly in adipose tissue.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 28732

    OMIM: 614285

    KEGG: hsa:338872

    STRING: 9606.ENSP00000333737

    UniGene: Hs.362854